HHS to Fund Regeneron's Efforts for Antibody Against Ebola

The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has entered into an agreement with Tarrytown-based Regeneron Pharmaceuticals, Inc to develop a treatment regimen that includes 3 monoclonal antibodies against the Ebola virus.

The company has developed the 3 fully-humanized monclonal antibodies using their propreitory VelociGene and VelocImmune technologies, and will receive $38 million over a 2-year period for further development and manufacturing of the monoclonal antibodies.

Read the associated press release by HHS here.